Fecal Bacterial Flora in Clostridium Difficile-Associated Diarrhea

Status Completed

Clinical Trial Summary

The investigators propose to study intensively the bacteriology of feces in C. difficile associated diarrheal disease, using a variety of conventional and very up-to-date techniques.

Clinical Trial Description

Clostridium difficile associated colitis is an increasing problem in hospitals throughout the developed world; the number of cases has increased, and the failure to respond to conventional therapy has become far more common. The investigators have recently documented in the medical literature (Clin Infect Dis, June, 2005; Lancet Infect Dis, August, 2005). Possible reasons for failure of treatment include persistence of C. difficile and/or imbalance of other bacterial flora in the colon. The bacteriology of fecal flora in C. difficile associated diarrhea has not been studied. ;

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00304876
Study type	Observational
Source	VA Medical Center, Houston
Contact
Status	Completed
Phase	N/A
Start date	October 2005
Completion date	January 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00382304` - A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea	Phase 2
Completed	`NCT03427229` - Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection	Phase 2
Completed	`NCT00106509` - A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea	Phase 3
Completed	`NCT00304369` - Response of Clostridium Difficile Infection to Metronidazole Therapy	N/A
Completed	`NCT00304889` - Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis	Phase 3
Completed	`NCT00304408` - Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody	Phase 4
Completed	`NCT00304356` - Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection	Phase 3
Completed	`NCT00182429` - Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment	Phase 3
Withdrawn	`NCT00304863` - Addition of Lactobacillus to Metronidazole in Treatment of CDAD	Phase 4